Single-ascending Dose Phase 1 Clinical Trial to Evaluate the Safety and PK of DA-5207 TDS in Healthy Adults
Launched by DONG-A ST CO., LTD. · Jul 8, 2019
Trial Information
Current as of May 03, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Health Male Volunteers (Age : 19\~55 years)
- • Body Weight : Male≥55kg, Female≥50kg
- • 18.5≤BMI\<25.0
- Exclusion Criteria:
- • Galactose intolerance, Lapp lactase deficiency, Glucose-galactose malabsorption
- • Allergy or Drug hypersensitivity
- • Clinically significant Medical History
- • AST, ALT \> Upper Normal Range\*1.25, eGFR\<60mL/min/1.73m²
- • Heavy alcohol intake (more than 210g/week)
- • Heavy smoker (more than 10 cigarettes/day)
- • Heavy caffeine intake
About Dong A St Co., Ltd.
Dong-A ST Co., Ltd. is a leading pharmaceutical and biotechnology company based in South Korea, dedicated to the research, development, and commercialization of innovative therapeutic solutions. With a robust portfolio spanning various therapeutic areas, including neurology, oncology, and cardiovascular health, Dong-A ST is committed to advancing healthcare through cutting-edge clinical research and high-quality products. The company emphasizes a patient-centered approach, collaborating with global partners to enhance treatment options and improve health outcomes worldwide. Through its rigorous clinical trials and commitment to scientific excellence, Dong-A ST strives to contribute meaningfully to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials